CLEAR LABELS Act
Senate CLEAR LABELS Act Would Require Drug Labels to Show Where Medicines Are Made
Legislative Progress
Key Points
- Congress is considering a new law that would require medicine labels to clearly show exactly where your drugs are made. Currently, it can be difficult for consumers to tell which company or country actually manufactured the specific ingredients in their prescriptions.
- Drug companies would have to list the name and location of the original factory that made the medicine's active ingredients, as well as the factory that finished the final product. This information could be printed directly on the packaging or accessed through a QR code or a website link.
- This change aims to give patients and doctors more transparency about the global supply chain for medicine. If there is a safety issue or a recall at a specific factory overseas, people would be able to check their own medicine bottles to see if their pills came from that location.
- The rules would apply to both the raw ingredients used to make drugs and the final pills or liquids sold to consumers. Companies would also be required to provide a paper copy of this manufacturing information to any individual who asks for it.
- If passed, the government would create specific rules for how these labels should look. These new requirements would start at least one year after the final rules are finished, giving drug companies time to update their packaging and systems.
Impact Analysis
Personal Impact
Life & Work
Small pharmaceutical manufacturers, packagers, and distributors would face new compliance costs to update their labeling, packaging systems, and potentially build or integrate with electronic portals (QR codes, searchable databases). While the bill allows a phase-in period of at least one year, the burden of tracking and disclosing full supply chain information may be proportionally heavier for smaller companies compared to large pharma firms.
Disabilities
Milestones
Committee on Health, Education, Labor, and Pensions. Hearings held.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
3 articles
Delegation for 1.30.26: labels
Senator Rick Scott introduced the CLEAR LABELS Act to mandate country-of-origin labeling for prescription drugs. The bill addresses concerns about the quality of generic drugs imported from China and India, noting that only 37% of pharmaceuticals consumed in 2024 were manufactured in the U.S.
US Senators Seek Drug Origin Labels
Senators Kirsten Gillibrand and Rick Scott introduced the CLEAR LABELS Act to require drug labels to disclose where medicines and their key ingredients are made. The move aims to increase transparency in a supply chain heavily reliant on overseas manufacturing in countries like China and India.
Rubio, Smith introduce bill to require country of origin labeling for drugs
In an earlier iteration of the policy, Senators Marco Rubio and Tina Smith introduced legislation to require drug labels to list the country of origin for active pharmaceutical ingredients. The bill seeks to reduce U.S. reliance on foreign drug manufacturing and improve supply chain oversight.
Source Information
Document Type
Congressional Bill
Official Title
CLEAR LABELS Act
Data Sources
Sponsor
Cosponsors
(10)Analysis generated by AI. Always verify with official sources.